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Background: The clinical consequences of chronic Stenotrophomonas maltophilia infection in cystic fibrosis (CF) patient are still unclear.
Method: All patients treated in the Copenhagen CF centre (N=278) from 1 January 2008 to 31 December 2009 were included. Each patient
chronically infected with S. maltophilia for at least 2 years without any other chronic Gram-negative infection were matched to two non-infected
CF controls.
Results: Twenty-one patients were chronically infected with S. maltophilia during the 2-year study period. Fifteen were infected for at least
2 years. The patients in the S. maltophilia group had a steeper decline (−3.2%/year vs. −0.3%/year) in FEV1 compared to the non-infected CF
controls (P=0.03). The rate of decline was the same as observed 3 years before the patients became chronically infected.
Discussions: Chronic infection with S. maltophilia does not lead to a steeper decline in lung function when compared to the period before chronic
infection.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Stenotrophomonas maltophilia; Cystic fibrosis; Lung infection1. Introduction
Patients with cystic fibrosis (CF) are often colonised with
opportunistic bacteria, causing bronco-pulmonary infections
that lead to deterioration in lung function and in the end
premature death [1,2]. The main bacterial pathogen is
Pseudomonas aeruginosa [3] but other Gram-negative bacteria
such as Burkholderia cepacia complex, Achromobacter
xylosoxidans and Stenotrophomonas maltophilia are emerging
pathogens, and some with increasing prevalence [4–6]. The
chronic infection with both A. xylosoxidans and B. cepacia
complex has been shown to cause a significant decline in lung
function [4,7].⁎ Corresponding author at: Department of Clinical Microbiology, 9301, Rigshospi
4013 6503.
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doi:10.1016/j.jcf.2011.03.006Data regarding the multi-resistant Gram-negative rod
S. maltophilia in CF patients are conflicting. Some authors
have recorded a decline in lung function in infected patients
[8–10] whereas others found no influence on the lung
function [11–13]. Newer data suggest that patient-to-patient
transmission may occur [14,15], and that patients chronically
infected with S. maltophilia is cable of rising a specific
antibody response against this bacteria associated with worse
lung function [16].
S. maltophilia is isolated from CF patients of all ages and the
U.S. Cystic Fibrosis Foundation's National Patient Registry
reported a stationary infection rate in all age groups around 10–
15% in 2008 [17]. A German study running over 6 months,talet, Juliane Maries Vej 22, DK-2100 Copenhagen Ø, Denmark. Tel./fax: +45
d by Elsevier B.V. All rights reserved.
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positive for S. maltophilia for the first time [18].
Since the clinical consequences of the infection still remain
unclear, the purpose of the present study is to evaluate the
consequences on lung function parameters in patients chroni-
cally infected with S. maltophilia as well as the prevalence and
incidence of the bacterium in our clinic.
2. Materials and methods
2.1. General care
In this historical cohort study all CF patients (N=278)
treated at the Copenhagen CF centre in the period from 1
January 2008 to 31 December 2009 were included. The patients
are seen once a month in the outpatient clinic for evaluation of
their clinical status. Sputum samples from the lower respiratory
tract are collected for microbiological examination, pulmonary
function tests are performed using a MasterLab Jäger,
Würtzburg, Germany spirometer, and BMI, and height is
measured. At least once a year, often more, precipitating
antibodies against P. aeruginosa, A. xylosoxidans, B. multi-
vorens complex and many other CF-related bacteria are
measured [19].
Patients with chronic P. aeruginosa, B. cepacia complex and
A. xylosoxidans are cohort isolated from other CF patients in the
outpatient clinic, in the wards as well as at social events such as
summer and winter camps to prevent patient-to-patient
transmission [20,21].
All patients are treated according to fixed guidelines
including PEP mask and daily administration of Pulmozyme
(recombinant human DNase, Roche, Basel, Switzerland) [4].
Patients with chronic lung infections are treated with daily
nebulised/inhaled and sometimes also oral antibiotic according
to resistance of the bacteria and receive i.v. antibiotics for
2 weeks every 3 months as previously described [4,20]. Patients
with chronic S. maltophilia infection are only treated if they
show sign of exacerbations and appropriate antibiotics are used
based on susceptibility testing.
2.2. Calculation of prevalence and incidence
Sputum and lower respiratory tract secretion were obtained
by coughing or endo-laryngeal suction. The samples were
Gram-stained and examined by microscopy and culture. The
numbers of respiratory samples positive for S. maltophilia in the
2-year period were counted.
We have applied same definitions for S. maltophilia
chronicity as for P. aeruginosa in our clinic, the patient are
chronically infected if S. maltophilia have been cultured every
month in 6 consecutive months, or less often when combined
with an increase in number of specific, precipitating antibodies
[22,23].
The yearly prevalence of colonised patients was calculated
as the number of patients with one or more positive S.
maltophilia samples divided by the number of patients treated
at the centre this year. The yearly incidence is calculated asthe number of patients who harboured S. maltophilia that year,
and were not chronically infected the year before. The yearly
prevalence of chronically infected patients was calculated as
the number of patients who harboured the bacteria chronically
that year divided by the whole population (N=278). To see if
the incidence and prevalence was increasing, the yearly
prevalence of colonised patients, the prevalence of chronically
infected patients and the incidence were calculated from 2003
to 2009.2.3. Impact of chronic S. maltophilia infection on the clinical
course of the CF lung disease
Patients chronically infected with S. maltophilia for at least
2 years, who did not have any other chronic pulmonary Gram-
negative infections, were matched to two CF controls with no
chronic Gram-negative infection in the control period. The
controls were matched by age (±3 years), gender and interval of
forced expiratory volume in 1 s in percent of predicted
(FEV1%). The patients were divided into the FEV1% of
predicted intervals according to the mean FEV1% of predicted
the year they became chronically infected. The FEV1% of
predicted intervals were 25–40%, N40–60%, N60–80% and
N80%. Because of age or infection status it was only possible to
find matched controls to fourteen of the fifteen patients in the
S. maltophilia group. Two controls were found to twelve of the
patients in the S. maltophilia group whereas only one control
was found to two of the patients in the S. maltophilia group. In
total twenty-six matched controls were found.
To see if any decline in lung function could be assigned to
the chronic S. maltophilia infection the change in lung function
in the S. maltophilia group were also compared to the change in
lung function in a period 3 years before they became chronically
infected, the same was done in the CF control group as
previously described in a study investigating the influence of
A. xylosoxidans infection on the lung function [4]. Two patients
in the S. maltophilia group did not have any FEV1% data prior
to infection as well as three pairs of controls because of young
age and were therefore not included in that analysis, but the
patient to whom it was not possible to find a control was
included in this analysis. The change in lung function was
determined as the slope (change in FEV1% of predicted per
year) of a linear regression in FEV1% of predicted measured
once a month. If two or more measurement a month were made,
the mean of these values were used.2.4. Measurement of specific anti-S. maltophilia antibodies
Precipitating antibodies were measured by crossed immuno-
electrophoresis, as previously described [2,20,22,23]. We
defined normal values as precipitating antibodies between 0
and 1 precipitins [22]. We investigated whether there is a
correlation between a high level of precipitating S. maltophilia
antibodies, and a decline in lung function, as previous described
for P. aeruginosa [23] and A. xylosoxidans [2,4].
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To see if any co-infections could have an influence on the
change in lung function, the co-infections in the S. maltophilia
group were compared to the co-infections in the CF control
group before and during chronic infection. The co-infections
were calculated as the percent of all cultures positive for a
certain bacteria.
2.6. Typing of S. maltophilia
To investigate if any of the patients shared the same clone of
S. maltophilia, indicating cross-infection, pulsed-field gel
electrophoresis (PFGE) was done on the latest isolate of
S. maltophilia from all 21 chronically infected patients. We
used Dra1 and Xba1 for restriction enzymes as previously
described [20,21] and compared PFGF patterns [21]. Due to
lack of samples, we did not investigate if the patients had the
same clone during the time of chronic infection or if re-infection
occurred therefore, we cannot state whether the infection was
caused by same clone, and thereby chronic, or if re-infection
occurred with a new clone. Investigations on patients
chronically infected with P. aeruginosa have shown that our
definition of chronic infection is very reliable in sputum
producing patients and chronically infected patients keep the
same genotypes for longer periods of time [24]. Based on this
we think that the infection with S. maltophilia is therefore most
likely to be chronic [22].
2.7. Statistical analysis
Students t-test were used to see if there were any difference
between age and FEV1% of predicted in the S. maltophilia
group and the CF control group. The statistical analysis on
the change in FEV1 per year was done using unpaired student's
t-test when patients in the S. maltophilia group were compared
to CF controls and paired student's t-test when patients in the
S. maltophilia group or CF control group were compared to
themselves. Level of significance was P≤0.05 (two-tailed).
To see if there was a difference in the number of patients
with other infections than S. maltophilia in the two groups we
used Fisher's exact test.
A linear regression analysis was used to see if any correlation
between a high level of precipitating S. maltophilia antibodies,
and a decline in lung function could be found. Additionally, it
was tested whether the slope was significantly different fromTable 1
The number of cystic fibrosis patients with S. maltophilia positive cultures from 20
Number of patients with
S. maltophilia/total
Number of S. m
positive culture
Patients with ≥1 82/278 499/1877
S. maltophilia positive cultures (30%) (27%)
Chronic 21/278 341/501
S. maltophilia infection (8%) (68%)
a Number of S. maltophilia positive cultures divided by the total number of cultures
chronically infected with S. maltophilia.zero. All the statistical analysis and figures are made using
GraphPad Prism version five to Windows 7.3. Results
3.1. General care, incidence and prevalence
From 2008 to 2009 eighty-two CF patients (30%), had at
least one positive culture for S. maltophilia with a median of
tree positive cultures per patient (range 1–27). Further
characteristic of patients with at least one positive S. maltophilia
culture from 2008 to 2009 are shown in Table 1.
In Fig. 1 the yearly prevalence of S. maltophilia infected
patients (a), the yearly prevalence of chronically S. maltophilia
infected patients (b) and the yearly incidence of S. maltophilia
infected patients (c) from 2003 to 2009 are shown. The yearly
prevalence in the period was stable around 23 to 25%. The
yearly prevalence in 2008 was 23%, 95% CI (0.19–0.29) and
21%, 95% CI (0.17–0.27) in 2009, respectively. The prevalence
of chronically infected S. maltophilia patients varied from 4%,
95% CI (0.02–0.07) in 2003 to 7%, 95% CI (0.04–0.10) in
2009. The yearly incidence from 2003 to 2009 varied from
22%, 95% CI (0.18–0.28) in 2006 to 16%, 95% CI (0.12–0.21)
in 2009 with a mean of 19%.
At the end of the study period (2008 to 2009) twenty-one
patients had been chronically infected with S. maltophilia
(median age 20 years (range 9–45 years)). Three of the twenty-
one chronically infected S. maltophilia patients were also
chronically infected with P. aeruginosa; these were excluded,
as we wanted to see if chronic S. maltophilia infection by itself
could lead to a decline in lung function. Three had been
chronically infected for less than 2 years, and in order to
evaluate the long-time importance of S. maltophilia these
patients were not included in our analysis. Data were collected
for the fifteen patients who had been chronically infected for
2 years or more, (median 42 months (range 24–107 months))
and did not have any other Gram-negative chronic infections
during the time of S. maltophilia chronic infection, none of the
fifteen patients got rid of the chronic infection during that
period.
The age and lung function of the S. maltophilia infected CF
patients and their CF controls are shown in Table 2.
No significant difference according to age, pancreatic
insufficiency, nutritional status and lung function in the two
groups at the beginning of the study period could be found.08 to 2009.
altophilia
s/total a
Median number of S. maltophilia
positive cultures per patient (range)
Median age (range)
3 19
(1–27) (2–60)
16 20
(4–27) (9–45)
in the eighty-two patients with one or more positive cultures, and in the patients
Fig. 1. The prevalence and incidence of S. maltophilia. The prevalence and
incidence of S. maltophilia positive patients per year treated at the Copenhagen
CF centre from 2003 to 2009. The prevalence of patients with one or more
positive S. maltophilia cultures (a), the prevalence of chronically S. maltophilia
infected patients (b) and the incidence of patients with one or more positive
S. maltophilia cultures (c).
Table 2
Demographic data in CF patients with chronic S. maltophilia infection and in CF
controls with no chronic Gram-negative infections.
Chronically infected
S. maltophilia patients
CF controls P-value
Number (males) 14 (8) 26 (15)
Median age (years) 14 (range 6–30) 11 (range 4–29) n.s.
Median FEV1% of
predicted at start
84 (range 48–116) 92 (range 48–126) n.s.
Mean BMI (range) 17.8 (14.0–23.8) 17.7 (14.8–23.9) n.s.
Class 1 or 2 mutation 12 20 n.s.
Pancreas sufficient 0 2 n.s.
Diabetes mellitus 3 3 n.s.
MBL values. Low or
insufficient (YA/0,
XA/0 or 0/0)
4 5 n.s.
Three of the 21 chronically infected patients were also chronically infected with
P. aeruginosa and were therefore excluded them from the analysis. Three other
had been chronically infected for less than 2 years and were therefore excluded.
Due to age and infection status it was only possible to find matched controls to
fourteen of the included fifteen patients in the S. maltophilia group.
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course of the CF lung disease
When the S. maltophilia group were compared to the CF
control group during the time of chronic infection a significant
difference in FEV1% of predicted per year were found
(P=0.03). The patients in the S. maltophilia group had a
significantly larger decline in FEV1 compared to the CF control
group. The mean change in FEV1 per year in the S. maltophilia
group was −3.2% of predicted per year (range −7.0 to +2.2)
(SD 2.7) and −0.3% in the control group (range −9.2 to +10.5)
(SD 4.4).
When the patients chronically infected with S. maltophilia
were compared to themselves in a period 3 years before they
became chronically infected, no significant change in FEV1 per
year was found. The mean change in FEV1% of predicted in the3-year period before chronic infection was −2.2% of predicted
per year (range −9.8 to +9.2) (SD 5.5) and −2.5% of predicted
per year (range −6.4 to +2.2) (SD 2.4) during the time of
chronic infection.
When the control group was compared to themselves 3 years
before, no significant change in lung function was found (data
not shown).
3.3. Co-infections
We investigated if any difference in co-infections could
explain the decline in lung function; patients chronically
infected with S. maltophilia had significantly more Aspergillus
(calculated as the percent of samples positive for Aspergillus per
patient) compared to the CF control group during time of
chronic infection, (mean 32% range 2% to 100%) (SD 33.6) of
all sputum samples in the S. maltophilia group and (mean 11%
range 0 to 98%) (SD 24.1) of all sputum samples in the CF
control group, (P=0.03).
In the period 3 years before chronic infection, the tendency
was the same although not formally significant (P=0.06) (mean
29% range 0% to 100%) (SD 36.6) in the S. maltophilia group
and (mean 11% range 0% to 88%) (SD 22.7) of all cultures in
the CF control group.
Also, significantly more patients (14/14) (100%) had one or
more cultures positive for Aspergillus compared to the CF
control group (15/25; 60%, P=0.007) during time of chronic
S. maltophilia infection. Also here the tendency was the same
3 years before chronic infection (10/14) (71%) in the S.
maltophilia group and (10/25) (40%) in the control group
although not significant.
Significantly more patients in the S. maltophilia group (4/14)
vs. (0/25) in the CF control group had one or more cultures
positive for nontuberculous mycobacteria (NTM) (P=0.01).
Two patients were NTM culture positive before they became
chronically infected with S. maltophilia and two during time of
chronic infection.
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been diagnosed with allergic broncopulmonary aspergillosis
(ABPA, 7/14) compared to the CF control group (2/25;
P=0.004). These analyses were made using Fisher's exact
test.
It was as previously mentioned only possible to find controls
to 14 of the 15 cases, and one of the controls did not have any
microbiology data 3 years before, and was therefore not
included in this analysis.
No significant difference was found according to
P. aeruginosa isolations between the two groups before chronicFig. 2. Pulsed-field-gel-electrophoresis (PFGE) pattern of the S. maltophilia strains fro
isolates from patient 13–21 (b). MW=molecular weight.infection (P=0.25), and during time of chronic infection
(P=0.5).
3.4. Typing of S. maltophilia
In order to investigate if S. maltophilia cross-infections
occurred among the patients, PFGE to test the clonality was
made on strains from the latest isolate from each of the 21
chronically infected patients. None of the patients shared the
same strain, also showed before, indicating that no cross-
infection has occurred, Fig. 2.m the 21 chronically infected patients.The isolates from patient 1–12 (a) and the
Fig. 3. Correlation between levels of precipitating antibodies and change in lung
function. No correlation was found between a high level of precipitating
S. maltophilia antibodies and a steep decline in lung function R2=0.06 and
P=0.37. n, precipitating antibodies, normal values 0–1.
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The level of precipitating antibodies against S. maltophilia
increased from a median of 1 precipitin during the first year of
chronic infection (range 0–11), to 6 in the second year of
chronic infection (range 0–19) and 6 in the third year (range
0–18).
In the control group the level of precipitating antibodies
remained normal (0–1).
3.6. Correlation between levels of specific anti-S. maltophilia
antibodies and the change in lung function
A subgroup of patients chronically infected with
S. maltophilia (N=4) had a rapid increase in the level of
precipitating antibodies against S. maltophilia to a level of at
least 12 antibodies, median 16 (range 12–18) during the first
3 years of chronic infection.
No significant difference in FEV1% of predicted per year
before or during chronic S. maltophilia infection was found
when the patients in the subgroup were compared to themselves
or to the group with a slower increase in antibodies (N=8;
Table 3). Three patients were only infected for 2 years and did
not have measurable precipitating antibodies in the third year
and were therefore not included in the analysis.
For all the patients in the S. maltophilia group it was tested
whether high levels of precipitating antibodies were correlated
with a larger decline in lung function, Fig. 3. High levels of
precipitating antibodies were reached, but no correlation was
found.
4. Discussion
We found a yearly prevalence of 24%, in 2008 and 21%, in
2009 of patients treated at the CF centre in Copenhagen with
one or more S. maltophilia positive sputum cultures. In contrast
to previously reported [5,6,25] no increasing prevalence was
observed in our centre. But our yearly prevalence is higher than
reported in other studies and centres elsewhere e.g. 4% by
Millar et al. [6], 7% by Spicuzza et al. [25], 15% by Marchac et
al. [11] and 12% by Emerson et al. [5]. The high prevalence in
our centre could be because we obtain sputum samples from ourTable 3
Change in FEV1% of predicted per year before and during chronic infection in
the patients with a slow and fast increase in precipitating antibodies.
Slow increase Fast increase P-value
Number of patients 8 4
Included in the analysis 7 a 3 a
Mean change in FEV1%
of predicted per year
before chronic infection
−4.8 (range −9.8
to +3.7)
2.6 (range −2.2
to +9.2)
n.s.
Mean change in FEV1%
of predicted per year
during chronic infection
−1.8 (range −4.9
to +2.2)
−2.7 (range −4
to −1.6)
n.s.
P-value n.s. n.s.
a Two patients (one in each group) were not included while no data were
available prior to infection because of young age.patients on a monthly basis and thereby might detect a higher
number of intermittently colonised patients.
Seven per cent of our patients are chronically infected with
S. maltophilia, and it is therefore important to determine
whether chronic infection with S. maltophilia has clinical
consequences. A number of studies have investigated this topic,
but the answers have been ambiguous. Some studies concluded
that a positive S. maltophilia culture was associated with lower
BMI and FEV1 compared to S. maltophilia negative patients
[13,26] and that patients with a S. maltophilia positive culture
have more advanced disease [27]. Others could not find similar
tendencies [12,28]. Demko et al. found that the 5-year survival
of patients with severe pulmonary status was worse in
S. maltophilia positive patients [29] and Karpati et al. that
S. maltophilia chronically infected patients had a significantly
decline in FEV1 at 2 years follow up which was not found in
patients chronically infected with P. aeruginosa, and they had
significantly worse lung function compared to controls infected
with P. aeruginosa [8].
None of these studies have compared patients with chronic
S. maltophilia infection without other chronic Gram-negative
infection to a CF control group without chronic Gram-negative
infection.
We compared a group of chronically S. maltophilia infected
CF patients to a CF control group with no chronic Gram-
negative infections and found that patients who had been
chronically infected with S. maltophilia for 2 years or more had
a significantly larger decline in lung function expressed as
change in FEV1% of predicted per year when compared to the
control group. However, when the patients in the S. maltophilia
group were compared to themselves in the period 3 years before
they became chronically infected this decline was also present at
that time, indicating that the decline for some reason had already
started before the patient became chronically infected.
A high level of precipitating antibodies or a steep increase
has been associated with poor prognosis in patients chronically
infected with P. aeruginosa [23] and A. xylosoxidans [4].
Waters et al. found that this also applied to S. maltophilia [16],
but we did not find this association in patients with chronic
S. maltophilia infection. The reason for this could be that
patients have a higher age at onset of chronic S. maltophilia
infection compared to P. aeruginosa [22], and that we looked at
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the time of serological examination.
We found that patients with chronic S. maltophilia infection
had a higher level of Aspergillus, which was also found by
Marchac et al. [11] and Valdezate et al. [30]. Furthermore,
patients chronically infected with S. maltophilia seem to have
more ABPA (50% of the patients vs. 8%), and more NTM
compared to the controls. These co-infections may have
contributed to the decline of lung function.
We found no evidence of cross-infection, indicating that
isolation of the patients infected with S. maltophilia is not
necessary, but of course a larger sample size must be
investigated in order to exclude this possibility, and it would
be interesting to see if a patient has the same clone during
chronic infection or if infection with a new clone is
occurring.
These results indicate that chronic infection with
S. maltophilia is correlated to a decline in lung function, but
this decline was already present prior to the chronic infection,
where the high prevalence of Aspergillus and ABPA and NTM
may have contributed.
This study has several limitations. The study population size
is rather small, and a larger, multicentre study is needed to see
whether our findings can be confirmed. Second, the controls
were matched on an age range ±3 years, which is a rather large
age span, and we were not able to find controls with the same
rates of Aspergillus and NTM. Third, some of the patients had
only been chronically infected for 2 years, which might not be
long enough time to detect a possible adverse effect of the
infection, It would therefore be very interesting to make a long-
term follow up study.
In conclusion CF patients with chronic S. maltophilia
infection experience a decline in lung function in contract to
matched CF controls with no chronic Gram-negative infection.
However, this decline of lung function was already ongoing
before the onset of chronic S. maltophilia infection and may be
due to a significantly increased prevalence of other infection
e.g. Aspergillus, ABPA and NTM.
Although a prominent antibody response to S. maltophilia
developed in some of the patients, this did not correlate to the
decline of lung function observed during time of chronic
infection. Long-term follow up studies are needed to evaluate
the long-term outcome of chronic S. maltophilia infection.References
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